|
|
| Countries covered: United States This Frost & Sullivan research service titled U.S. Research ELISA Markets provides revenue forecasts for the overall market. It provides in-depth analyses of market-wide and segment-specific drivers, restraints, and challenges, with the corresponding strategic recommendations. In this research, Frost & Sullivan's expert analysts thoroughly examine the following research ELISA markets: kits and development components. Market Overview Research ELISA’s Established Credentials Help it Weather Competition from Multiplex Proteomic Arrays After a glorious 37-year run as a reliable and trusted technology for analyte quantitation, the research enzyme-linked immunosorbent assay (ELISA) technique has reached market maturity. It is drawing on its entrenched reputation for quality results and reproducibility to stave off the challenge mounted by newer multiplex proteomic array technologies. This new-age technology scores over the single-analyte quantitation technique of ELISA by offering high throughput capability and allowing researchers to measure multiple analytes simultaneously. "While the increased use of multiplex proteomic array technologies has stalled the research ELISA market, new ELISA products remain profitable at the provider level," says the analyst of this research service. "Market participants are discovering that many laboratories still prefer the ELISA technique or continue using the technology for secondary validation after multiplexing." ELISA suppliers can also position their products as the ideal tools for researchers that do not need the advantages of multiplexing, focus only on a few analytes, and require high assay sensitivity. This strategy can help diffuse the threat of price instability, which is consequent to the commoditization of products for popular analytes. With over 60 participants serving in the ELISA market, it is vital to focus new products on areas of research where multiplex arrays have not been developed. "Many providers are expected to slow the expansion of their ELISA portfolios or focus on niche markets and unique species to circumvent growing competition from proteomic arrays," observes the analyst. "ELISA providers must adapt their strategies to complement multiplex platforms rather than try to compete head-on." Increasingly, companies have opted to develop their own multiplex assay portfolios to take advantage of the new technology and expand customer options. |
More United States Allergy/Immunology Reports
Cough, Cold and Allergy (Hay Fever) Remedies in the US by
Euromonitor International
In 2011, Chattem Inc’s Allegra brand of antihistamine/allergy remedies (systemic) switched from Rx-to-OTC, representing one of the largest switches in the segment’s history. First stocked ...
Cough & Cold Medicine Manufacturing OTC in the US - Industry Market Research Report by
IBISWorld
Get well: Seasonal colds will facilitate growth, but prescription drugs will limit demand Cough & Cold Medicine Manufacturing OTC Get well The necessary nature of cough and cold ...
Cough, Cold and Allergy (hay Fever) Remedies - USA by
Euromonitor International
Two very important active ingredients in cough and cold products were the subject of heated regulatory discussion in 2010. Pseudoephedrine (PSE), a powerful decongestant, attracted ...
Gluten-Free Foods and Beverages in the U.S., 3rd Edition by
Packaged Facts
"Are you gluten-free?" The term describes more than the sector of the food and beverage industry that has morphed from specialty niche to mainstream ...
Allergy Drugs by
Global Industry Analysts
This report analyzes the US Market for Allergy Drugs in US$ Million by the following types - Prescription Antihistamines, Prescription Corticosteroids, and OTC Allergy Drugs. ...
See all reports like this >>
More United States Reports
e-Discovery Software Publishing in the US - Industry Market Research Report by
IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...
D&B Country RiskLine Report: The United States of America by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by
Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>
